Introduction to Biological and Small Molecule Drug Research and Development

Produk Detail:
  • Author : C. Robin Ganellin
  • Publisher : Academic Press
  • Pages : 472 pages
  • ISBN : 0123977703
  • Rating : /5 from reviews
CLICK HERE TO GET THIS BOOK >>>Introduction to Biological and Small Molecule Drug Research and Development

Download or Read online Introduction to Biological and Small Molecule Drug Research and Development full in PDF, ePub and kindle. this book written by C. Robin Ganellin and published by Academic Press which was released on 07 May 2013 with total page 472 pages. We cannot guarantee that Introduction to Biological and Small Molecule Drug Research and Development book is available in the library, click Get Book button and read full online book in your kindle, tablet, IPAD, PC or mobile whenever and wherever You Like. Introduction to Biological and Small Molecule Drug Research and Development provides, for the first time, an introduction to the science behind successful pharmaceutical research and development programs. The book explains basic principles, then compares and contrasts approaches to both biopharmaceuticals (proteins) and small molecule drugs, presenting an overview of the business and management issues of these approaches. The latter part of the book provides carefully selected real-life case studies illustrating how the theory presented in the first part of the book is actually put into practice. Studies include Herceptin/T-DM1, erythropoietin (Epogen/Eprex/NeoRecormon), anti-HIV protease inhibitor Darunavir, and more. Introduction to Biological and Small Molecule Drug Research and Development is intended for late-stage undergraduates or postgraduates studying chemistry (at the biology interface), biochemistry, medicine, pharmacy, medicine, or allied subjects. The book is also useful in a wide variety of science degree courses, in post-graduate taught material (Masters and PhD), and as basic background reading for scientists in the pharmaceutical industry. For the first time, the fundamental scientific principles of biopharmaceuticals and small molecule chemotherapeutics are discussed side-by-side at a basic level Edited by three senior scientists with over 100 years of experience in drug research who have compiled the best scientific comparison of small molecule and biopharmaceuticals approaches to new drugs Illustrated with key examples of important drugs that exemplify the basic principles of pharmaceutical drug research and development

Introduction to Biological and Small Molecule Drug Research and Development

Introduction to Biological and Small Molecule Drug Research and Development
  • Author : C. Robin Ganellin,Roy Jefferis,Stanley M. Roberts
  • Publisher : Academic Press
  • Release : 07 May 2013
GET THIS BOOK Introduction to Biological and Small Molecule Drug Research and Development

Introduction to Biological and Small Molecule Drug Research and Development provides, for the first time, an introduction to the science behind successful pharmaceutical research and development programs. The book explains basic principles, then compares and contrasts approaches to both biopharmaceuticals (proteins) and small molecule drugs, presenting an overview of the business and management issues of these approaches. The latter part of the book provides carefully selected real-life case studies illustrating how the theory presented in the first part of the

Introduction to Biological and Small Molecule Drug Research and Development

Introduction to Biological and Small Molecule Drug Research and Development
  • Author : James Samanen
  • Publisher : Elsevier Inc. Chapters
  • Release : 07 May 2013
GET THIS BOOK Introduction to Biological and Small Molecule Drug Research and Development

Successful drugs have a good return on investment by bringing in considerably more revenue than the expenses of discovery, development, and manufacturing. Successful drugs pay for all drug projects, those that fail and those that have yet to fail or succeed. Most research and development (R&D) projects fail. Since R&D is the future of the company, a lot is at stake in the business of R&D. This chapter considers the organization of biopharmaceutical R&D, as well

Introduction to Biological and Small Molecule Drug Research and Development

Introduction to Biological and Small Molecule Drug Research and Development
  • Author : Michael Stocks
  • Publisher : Elsevier Inc. Chapters
  • Release : 07 May 2013
GET THIS BOOK Introduction to Biological and Small Molecule Drug Research and Development

Drug discovery of small molecules from target selection through to clinical evaluation is a very complex, challenging but rewarding area of drug discovery. There are many obstacles along the journey from initial hit-finding activities, through optimization of compounds and eventually to delivery of robust candidate drugs (CDs) for clinical evaluation. This chapter presents key issues and literature solutions with respect to the optimization of hits into CDs. Details of the key hit-finding activities namely high-throughput screening, virtual screening, natural products,

Introduction to Biological and Small Molecule Drug Research and Development

Introduction to Biological and Small Molecule Drug Research and Development
  • Author : James Samanen
  • Publisher : Elsevier Inc. Chapters
  • Release : 07 May 2013
GET THIS BOOK Introduction to Biological and Small Molecule Drug Research and Development

Biotechnology has given rise to a broad range of biotherapies or biologics, including biomolecular drugs, vaccines, cell or gene therapies. This chapter focuses on biomolecular drugs, namely monoclonal antibodies (Mabs), cytokines, tissue growth factors and therapeutic proteins. Prior to the US approval of recombinant human insulin in 1982, biomolecular drugs were extracted from natural sources. The tools of molecular biology have dramatically increased the discovery and development of new biopharmaceuticals. The most obvious difference between small-molecule drugs (SMDs) and biomolecular drugs

Introduction to Biological and Small Molecule Drug Research and Development

Introduction to Biological and Small Molecule Drug Research and Development
  • Author : Jill M. Carton,William R. Strohl
  • Publisher : Elsevier Inc. Chapters
  • Release : 07 May 2013
GET THIS BOOK Introduction to Biological and Small Molecule Drug Research and Development

Throughout human history, the morbidity and mortality associated with human disease has driven medical science into an ever-expanding quest for treatment and cure. Over the past century, a therapeutic approach complementing chemical drugs has been developing which uses proteins and peptides in the treatment of disease. Many innovative protein therapeutic platforms are currently being employed and continue to be developed to attain cures in areas of unmet medical need; these include direct copies of natural protein structure and function as

Introduction to Biological and Small Molecule Drug Research and Development

Introduction to Biological and Small Molecule Drug Research and Development
  • Author : C. Robin Ganellin
  • Publisher : Elsevier Inc. Chapters
  • Release : 07 May 2013
GET THIS BOOK Introduction to Biological and Small Molecule Drug Research and Development

A brief introduction to cholesterol and lipoproteins is followed by a short account of the types of drugs which reduce cholesterol levels (bile sequestrants, hypocholesterolaemics, fibrates as acyl-CoA:cholesterol acyltransferase (ACAT) inhibitors, statins as 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, and saponins). This chapter continues with a background to the extraordinary research effort at the Schering-Plough Research Institute on ACAT inhibitors and the structure–activity studies that led to the lead cholesterol absorption inhibitor, the azetidinone SCH 48461. Impressive studies of the

Introduction to Biological and Small Molecule Drug Research and Development

Introduction to Biological and Small Molecule Drug Research and Development
  • Author : Jennifer Ann Littlechild
  • Publisher : Elsevier Inc. Chapters
  • Release : 07 May 2013
GET THIS BOOK Introduction to Biological and Small Molecule Drug Research and Development

This chapter covers the general features of protein structure and recent advances in structural bioinformatics. The importance of the three-dimensional structure of the protein target in order to understand its mechanism of action as an aid for drug design is illustrated by specific examples of enzyme inhibition, receptor interactions and drugs binding to structural proteins. The impact of proteomics and bioinformatics is stressed, while protein interactions with other proteins and different biological macromolecules are discussed.

Introduction to Biological and Small Molecule Drug Research and Development

Introduction to Biological and Small Molecule Drug Research and Development
  • Author : Denis Mulleman,Marc Ohresser,Hervé Watier
  • Publisher : Elsevier Inc. Chapters
  • Release : 07 May 2013
GET THIS BOOK Introduction to Biological and Small Molecule Drug Research and Development

Parallel studies in septic shock and cancer led to the discovery of the endogenous factors named cachectin and tumour necrosis factor (TNF), respectively, that were shown to be structurally and functionally similar. Further studies identified two forms of TNF, TNF-α and TNF-β. The anticipation that specific anti-TNF antibody might have therapeutic potential in the resolution of sepsis was not realized; however, anti-TNF-α agents have been shown to have dramatic therapeutic efficacy in a number of inflammatory diseases. Currently, there are

Introduction to Biological and Small Molecule Drug Research and Development

Introduction to Biological and Small Molecule Drug Research and Development
  • Author : Wolfgang Jelkmann
  • Publisher : Elsevier Inc. Chapters
  • Release : 07 May 2013
GET THIS BOOK Introduction to Biological and Small Molecule Drug Research and Development

The renal hormone erythropoietin (Epo) is essential for the viability and proliferation of the erythrocytic progenitors generating reticulocytes in the bone marrow. Human Epo consists of a chain of 165 amino acid residues and four glycans. The synthesis of Epo is strongly stimulated by hypoxia. Epo deficiency is the primary cause of the anaemia in chronic kidney disease (CKD). For anaemia treatment recombinant human Epo (rhEpo/epoetin and epoetin) is very useful. The drug substance is generally manufactured in EPO complementary

Introduction to Biological and Small Molecule Drug Research and Development

Introduction to Biological and Small Molecule Drug Research and Development
  • Author : Arun K. Ghosh,Bruno D. Chapsal
  • Publisher : Elsevier Inc. Chapters
  • Release : 07 May 2013
GET THIS BOOK Introduction to Biological and Small Molecule Drug Research and Development

The development of HIV protease inhibitors (PIs) and their inclusion in highly active antiretroviral therapies (HAARTs) marked the beginning of a treatment breakthrough in the management of human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS). The HAART treatment regimen can cut HIV viral load to undetectable levels. Nonetheless, the rapid emergence of HIV drug resistance has continued to seriously compromise long-term treatment options for HIV-infected patients. Our structure-based design strategy to develop PIs that specifically target the enzyme's backbone atoms

Introduction to Biological and Small Molecule Drug Research and Development

Introduction to Biological and Small Molecule Drug Research and Development
  • Author : Charles W. Richard
  • Publisher : Elsevier Inc. Chapters
  • Release : 07 May 2013
GET THIS BOOK Introduction to Biological and Small Molecule Drug Research and Development

Lysosomal storage disorders (LSDs) represent a group of about 50 genetic disorders caused by deficiencies of lysosomal proteins. The missing lysosomal protein causes a build-up of toxic metabolites in the cells of patients, leading to progressive multisystem disease and premature death. Although individually rare, the combined prevalence of all lysosomal disorders is estimated to be 1 in 8000 births. This chapter describes progress in several different LSD treatment modalities including enzyme replacement therapy, haematopoietic stem cell therapy, chaperone (enzyme stabilization) therapy, and substrate

Introduction to Biological and Small Molecule Drug Research and Development

Introduction to Biological and Small Molecule Drug Research and Development
  • Author : Andy Barker,David Anrews
  • Publisher : Elsevier Inc. Chapters
  • Release : 07 May 2013
GET THIS BOOK Introduction to Biological and Small Molecule Drug Research and Development

The epidermal growth factor receptor (EGFR) tyrosine kinase is a target for cancer chemotherapy. This chapter describes the discovery of small-molecule inhibitors of the kinase, their characterization and the medicinal chemistry programme that resulted in the identification of gefitinib. The development and studies undertaken to progress the drug in the clinic are presented together with a brief summary of other inhibitors of the EGFR kinase and their properties.

Introduction to Biological and Small Molecule Drug Research and Development

Introduction to Biological and Small Molecule Drug Research and Development
  • Author : Matthew P. Coghlan,David Fairman
  • Publisher : Elsevier Inc. Chapters
  • Release : 07 May 2013
GET THIS BOOK Introduction to Biological and Small Molecule Drug Research and Development

The increasing global prevalence of type 2 diabetes represents a significant burden of disease for afflicted patients and for health care systems. In the developed world poorly controlled diabetes is the leading cause of non-traumatic amputation, blindness and end-stage renal disease requiring dialysis and kidney transplant. Additionally, diabetes represents a significant risk factor for the development of cardiovascular disease with its associated morbidity and premature death. Currently available glucose lowering drugs used to treat type 2 diabetes do not impede progression of

Introduction to Biological and Small Molecule Drug Research and Development

Introduction to Biological and Small Molecule Drug Research and Development
  • Author : null Hasmann
  • Publisher : Elsevier Inc. Chapters
  • Release : 07 May 2013
GET THIS BOOK Introduction to Biological and Small Molecule Drug Research and Development

HER2 (ErbB-2) is a member of the human epidermal growth factor receptor tyrosine kinase family which is involved in the regulation of cell proliferation, survival and differentiation. Soon after its discovery, HER2 was shown frequently to be overexpressed in breast cancer and was associated with a worse prognosis. It was identified as a target for drug development and molecular cloning of the gene and expression in cell lines provided a vehicle for the selection of HER2-specific antibodies. The monoclonal

Introduction to Biological and Small Molecule Drug Research and Development

Introduction to Biological and Small Molecule Drug Research and Development
  • Author : Stanley M. Roberts
  • Publisher : Elsevier Inc. Chapters
  • Release : 07 May 2013
GET THIS BOOK Introduction to Biological and Small Molecule Drug Research and Development

Menopause affects the quality of life for women, sometimes severely. The symptoms can be addressed by treatment with steroids, namely, an oestrogen alone or an oestrogen with a progestin. The treatment is called hormone replacement therapy (HRT). However, for years, HRT has been associated with side effects, for instance, an increased risk of breast or endometrial cancer and stroke. The potentially positive effect of reducing some forms of heart disease is still a matter of debate, while the HRT-related decrease